The novel drug delivery systems market size has grown rapidly in recent years. It will grow from $117.66 billion in 2025 to $129.45 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, limitations of conventional drug delivery methods, growth in oncology and biologics pipeline, rising healthcare expenditure, advancements in polymer and nanotechnology.
The novel drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $187.53 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to surge in personalized and precision medicine, growing demand for targeted cancer therapies, increasing investment in pharmaceutical r&d, expansion of biologics and biosimilars, regulatory support for advanced drug delivery technologies. Major trends in the forecast period include expansion of targeted and personalized drug delivery, rising adoption of lipid and polymeric nanoparticles, growth in long-acting and controlled release formulations, increased focus on non-invasive and patient-centric delivery routes, accelerated r&d in combination and hybrid ndds platforms.
The increasing cases of neurological disorders are anticipated to drive growth in the novel drug delivery systems market. Neurological disorders like stroke involve the sudden loss of neurological function caused by interrupted blood flow to the brain, either through a blockage (ischemic stroke) or a blood vessel rupture (hemorrhagic stroke), resulting in brain damage and possible long-term impairments in cognition, sensation, or movement. Factors such as aging populations, the rising prevalence of lifestyle-related conditions including hypertension, diabetes, and obesity, as well as greater exposure to chronic stress and environmental risks, are contributing to the increase in neurological disorders. Novel drug delivery systems aid in treating these disorders by providing targeted and controlled delivery of medications across the blood-brain barrier. For example, in November 2024, the National Health Service (NHS) England reported that stroke admissions in England reached 111,137 in 2023/24, with the highest rise seen in the 50-59 age group, which had 12,533 new cases. Consequently, the growing incidence of neurological disorders is fueling the novel drug delivery systems market.
Leading companies in the novel drug delivery systems market are innovating with products like oral thin films to improve patient compliance and treatment effectiveness. Oral thin films are rapidly dissolving strips applied inside the mouth that deliver drugs directly into the bloodstream through the mucosal lining. For example, in February 2024, CD Formulation, a US pharmaceutical formulation company, introduced Oral Thin Film Technology. This technology enables quick drug absorption by bypassing the gastrointestinal tract and liver metabolism, making it ideal for patients who have difficulty swallowing. It also allows precise dosing and faster onset of effects, enhancing treatment accuracy and convenience across multiple therapies.
In April 2023, DifGen Pharmaceuticals LLC, a US-based pharmaceutical firm, acquired Aveva Drug Delivery Services Inc. for an undisclosed sum. This acquisition is intended to expand DifGen’s expertise in complex dosage forms by adding US research and manufacturing capabilities for transdermal and thin film drug delivery systems. Aveva Drug Delivery Services Inc. specializes in transdermal drug delivery and oral dissolvable films.
Major companies operating in the novel drug delivery systems market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche AG, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Gilead Sciences, Amgen Inc, Teva Pharmaceutical Industries Ltd, Otsuka Pharmaceutical Co Ltd, Regeneron Pharmaceuticals, Samyang Holdings Corporation, Galen Limited, Catalent Inc, Evonik Industries AG.
North America was the largest region in the novel drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the novel drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the novel drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the novel drug delivery systems market by increasing costs for imported raw materials such as polymers, lipids, and specialized nanoparticles, impacting overall manufacturing economics and pricing strategies. these effects are most pronounced in formulation types like liposomes and nanoparticles and across regions reliant on cross-border pharmaceutical supply chains, particularly asia-pacific and europe. however, tariffs are also encouraging localization of manufacturing, regional supply chain diversification, and domestic innovation, which may strengthen long-term market resilience and self-sufficiency.
The novel drug delivery systems market research report is one of a series of new reports that provides novel drug delivery systems market statistics, including novel drug delivery systems industry global market size, regional shares, competitors with a novel drug delivery systems market share, detailed novel drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the novel drug delivery systems industry. This novel drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Novel drug delivery systems are advanced pharmaceutical technologies aimed at improving the effectiveness, safety, bioavailability, and targeted delivery of medications by precisely controlling the rate, timing, and location of drug release in the body. These systems address the shortcomings of traditional delivery methods, enhance treatment outcomes, and boost patient adherence across diverse medical and therapeutic fields.
Key formulation types within novel drug delivery systems include liposomes, nanoparticles, microspheres, hydrogels, and dendrimers. Liposomes are spherical vesicles made of phospholipid bilayers that encapsulate drugs, allowing for targeted delivery, controlled release, and minimized drug toxicity. The delivery modes include targeted, controlled, and modulated drug delivery systems, which are administered through various routes such as oral, injectable, pulmonary, transdermal, and others. These systems are applied in multiple therapeutic areas including cancer, cardiovascular diseases, neurological disorders, infectious diseases, and autoimmune diseases, serving end-users like hospitals, specialty clinics, research centers, and more.
The novel drug delivery systems market consists of sales of implants, micelles, exosomes, prodrugs, nasal drug delivery devices, buccal drug delivery films, and ocular drug delivery inserts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The novel drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $187.53 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to surge in personalized and precision medicine, growing demand for targeted cancer therapies, increasing investment in pharmaceutical r&d, expansion of biologics and biosimilars, regulatory support for advanced drug delivery technologies. Major trends in the forecast period include expansion of targeted and personalized drug delivery, rising adoption of lipid and polymeric nanoparticles, growth in long-acting and controlled release formulations, increased focus on non-invasive and patient-centric delivery routes, accelerated r&d in combination and hybrid ndds platforms.
The increasing cases of neurological disorders are anticipated to drive growth in the novel drug delivery systems market. Neurological disorders like stroke involve the sudden loss of neurological function caused by interrupted blood flow to the brain, either through a blockage (ischemic stroke) or a blood vessel rupture (hemorrhagic stroke), resulting in brain damage and possible long-term impairments in cognition, sensation, or movement. Factors such as aging populations, the rising prevalence of lifestyle-related conditions including hypertension, diabetes, and obesity, as well as greater exposure to chronic stress and environmental risks, are contributing to the increase in neurological disorders. Novel drug delivery systems aid in treating these disorders by providing targeted and controlled delivery of medications across the blood-brain barrier. For example, in November 2024, the National Health Service (NHS) England reported that stroke admissions in England reached 111,137 in 2023/24, with the highest rise seen in the 50-59 age group, which had 12,533 new cases. Consequently, the growing incidence of neurological disorders is fueling the novel drug delivery systems market.
Leading companies in the novel drug delivery systems market are innovating with products like oral thin films to improve patient compliance and treatment effectiveness. Oral thin films are rapidly dissolving strips applied inside the mouth that deliver drugs directly into the bloodstream through the mucosal lining. For example, in February 2024, CD Formulation, a US pharmaceutical formulation company, introduced Oral Thin Film Technology. This technology enables quick drug absorption by bypassing the gastrointestinal tract and liver metabolism, making it ideal for patients who have difficulty swallowing. It also allows precise dosing and faster onset of effects, enhancing treatment accuracy and convenience across multiple therapies.
In April 2023, DifGen Pharmaceuticals LLC, a US-based pharmaceutical firm, acquired Aveva Drug Delivery Services Inc. for an undisclosed sum. This acquisition is intended to expand DifGen’s expertise in complex dosage forms by adding US research and manufacturing capabilities for transdermal and thin film drug delivery systems. Aveva Drug Delivery Services Inc. specializes in transdermal drug delivery and oral dissolvable films.
Major companies operating in the novel drug delivery systems market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche AG, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Gilead Sciences, Amgen Inc, Teva Pharmaceutical Industries Ltd, Otsuka Pharmaceutical Co Ltd, Regeneron Pharmaceuticals, Samyang Holdings Corporation, Galen Limited, Catalent Inc, Evonik Industries AG.
North America was the largest region in the novel drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the novel drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the novel drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the novel drug delivery systems market by increasing costs for imported raw materials such as polymers, lipids, and specialized nanoparticles, impacting overall manufacturing economics and pricing strategies. these effects are most pronounced in formulation types like liposomes and nanoparticles and across regions reliant on cross-border pharmaceutical supply chains, particularly asia-pacific and europe. however, tariffs are also encouraging localization of manufacturing, regional supply chain diversification, and domestic innovation, which may strengthen long-term market resilience and self-sufficiency.
The novel drug delivery systems market research report is one of a series of new reports that provides novel drug delivery systems market statistics, including novel drug delivery systems industry global market size, regional shares, competitors with a novel drug delivery systems market share, detailed novel drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the novel drug delivery systems industry. This novel drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Novel drug delivery systems are advanced pharmaceutical technologies aimed at improving the effectiveness, safety, bioavailability, and targeted delivery of medications by precisely controlling the rate, timing, and location of drug release in the body. These systems address the shortcomings of traditional delivery methods, enhance treatment outcomes, and boost patient adherence across diverse medical and therapeutic fields.
Key formulation types within novel drug delivery systems include liposomes, nanoparticles, microspheres, hydrogels, and dendrimers. Liposomes are spherical vesicles made of phospholipid bilayers that encapsulate drugs, allowing for targeted delivery, controlled release, and minimized drug toxicity. The delivery modes include targeted, controlled, and modulated drug delivery systems, which are administered through various routes such as oral, injectable, pulmonary, transdermal, and others. These systems are applied in multiple therapeutic areas including cancer, cardiovascular diseases, neurological disorders, infectious diseases, and autoimmune diseases, serving end-users like hospitals, specialty clinics, research centers, and more.
The novel drug delivery systems market consists of sales of implants, micelles, exosomes, prodrugs, nasal drug delivery devices, buccal drug delivery films, and ocular drug delivery inserts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Novel Drug Delivery Systems Market Characteristics
3. Novel Drug Delivery Systems Market Supply Chain Analysis
4. Global Novel Drug Delivery Systems Market Trends and Strategies
5. Novel Drug Delivery Systems Market Analysis of End Use Industries
7. Global Novel Drug Delivery Systems Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Novel Drug Delivery Systems Total Addressable Market (TAM) Analysis for the Market
9. Novel Drug Delivery Systems Market Segmentation
10. Novel Drug Delivery Systems Market Regional and Country Analysis
11. Asia-Pacific Novel Drug Delivery Systems Market
12. China Novel Drug Delivery Systems Market
13. India Novel Drug Delivery Systems Market
14. Japan Novel Drug Delivery Systems Market
15. Australia Novel Drug Delivery Systems Market
16. Indonesia Novel Drug Delivery Systems Market
17. South Korea Novel Drug Delivery Systems Market
18. Taiwan Novel Drug Delivery Systems Market
19. South East Asia Novel Drug Delivery Systems Market
20. Western Europe Novel Drug Delivery Systems Market
21. UK Novel Drug Delivery Systems Market
22. Germany Novel Drug Delivery Systems Market
23. France Novel Drug Delivery Systems Market
24. Italy Novel Drug Delivery Systems Market
25. Spain Novel Drug Delivery Systems Market
26. Eastern Europe Novel Drug Delivery Systems Market
27. Russia Novel Drug Delivery Systems Market
28. North America Novel Drug Delivery Systems Market
29. USA Novel Drug Delivery Systems Market
30. Canada Novel Drug Delivery Systems Market
31. South America Novel Drug Delivery Systems Market
32. Brazil Novel Drug Delivery Systems Market
33. Middle East Novel Drug Delivery Systems Market
34. Africa Novel Drug Delivery Systems Market
36. Novel Drug Delivery Systems Market Competitive Landscape and Company Profiles
37. Novel Drug Delivery Systems Market Other Major and Innovative Companies
40. Novel Drug Delivery Systems Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Novel Drug Delivery Systems Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses novel drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for novel drug delivery systems? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The novel drug delivery systems market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Formulation Type: Liposomes; Nanoparticles; Microspheres; Hydrogels; Dendrimers2) By Mode Of Novel Drug Delivery System (NDDS): Targeted Drug Delivery Systems; Controlled Drug Delivery Systems; Modulated Drug Delivery Systems
3) By Route: Oral Drug Delivery Systems; Injectable Drug Delivery Systems; Pulmonary Drug Delivery Systems; Transdermal Drug Delivery Systems; Other Routes
4) By Therapeutic Area: Cancer; Cardiovascular Diseases; Neurological Disorders; Infectious Diseases; Autoimmune Diseases
5) By End-User: Hospital; Specialty Clinics; Research Centers; Other End-Users
Subsegments:
1) By Liposomes: PEGylated Liposomes; Cationic Liposomes; Stealth Liposomes; Immunoliposomes2) By Nanoparticles: Polymeric Nanoparticles; Lipid Nanoparticles; Metallic Nanoparticles; Nanocrystals
3) By Microspheres: Biodegradable Microspheres; Magnetic Microspheres; Radioactive Microspheres; Mucoadhesive Microspheres
4) By Hydrogels: Thermosensitive Hydrogels; Ph-Responsive Hydrogels; Injectable Hydrogels; Smart Hydrogels
5) By Dendrimers: PAMAM Dendrimers; PPI Dendrimers; Pegylated Dendrimers; Hybrid Dendrimers
Companies Mentioned: Pfizer Inc; Johnson And Johnson; F Hoffmann La Roche AG; Merck And Co Inc; AbbVie Inc; Bayer AG; Sanofi SA; Bristol Myers Squibb Company; AstraZeneca PLC; Novartis AG; GlaxoSmithKline PLC; Takeda Pharmaceutical Company Limited; Eli Lilly And Company; Gilead Sciences; Amgen Inc; Teva Pharmaceutical Industries Ltd; Otsuka Pharmaceutical Co Ltd; Regeneron Pharmaceuticals; Samyang Holdings Corporation; Galen Limited; Catalent Inc; Evonik Industries AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Novel Drug Delivery Systems market report include:- Pfizer Inc
- Johnson And Johnson
- F Hoffmann La Roche AG
- Merck And Co Inc
- AbbVie Inc
- Bayer AG
- Sanofi SA
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Novartis AG
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Eli Lilly And Company
- Gilead Sciences
- Amgen Inc
- Teva Pharmaceutical Industries Ltd
- Otsuka Pharmaceutical Co Ltd
- Regeneron Pharmaceuticals
- Samyang Holdings Corporation
- Galen Limited
- Catalent Inc
- Evonik Industries AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 129.45 Billion |
| Forecasted Market Value ( USD | $ 187.53 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
